ENDOMETRIAL NEOPLASMS
Clinical trials for ENDOMETRIAL NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL NEOPLASMS trials appear
Sign up with your email to follow new studies for ENDOMETRIAL NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New drug targets HER2-Positive tumors in four cancer types
Disease control OngoingThis study tests an experimental drug called disitamab vedotin in 120 adults with advanced head/neck, lung, endometrial, or ovarian cancers that have the HER2 marker. The drug is designed to stick to cancer cells and kill them. Participants receive the drug every two weeks to see…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Immunotherapy drug shows promise against tough uterine cancer
Disease control OngoingThis study tests whether the immunotherapy drug pembrolizumab works better than standard chemotherapy for women with a certain type of advanced or returning endometrial cancer (dMMR). About 280 women who have not had chemotherapy before will take part. The goal is to see if pembr…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for advanced endometrial cancer: drug combo shows promise
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy, followed by maintenance therapy with or without olaparib, can help people with newly diagnosed advanced or recurrent endometrial cancer live longer without their cancer growing. About 805 …
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New combo therapy aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug, E7386, combined with other anticancer drugs for people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose. About 301 participants will be involved, and the study foc…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated May 06, 2026 16:02 UTC